Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06319443 · ClinicalTrials.gov registry record · NA
Daily Vinegar Ingestion and 24-Hour Blood Glucose Control
A NA study of Glucose Intolerance, sponsored by Arizona State University.
- Completed
- Registry status
- NA
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT06319443: Completed NA study of Glucose Intolerance, sponsored by Arizona State University.
NCT06319443 is a NA study of Glucose Intolerance that has completed, run by Arizona State University. The registered enrollment target is 10 participants, below the 3,858-participant average among 14 other Glucose Intolerance trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06319443, a NA study of Glucose Intolerance, has completed, sponsored by Arizona State University.
- COMPLETED
- Registry status
- NA
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
When linking dietary interventions and blood glucose management, much of the existing research - particularly studies exploring the effects of vinegar - has relied on discrete readings from the conventional testing methods: blood samples or glucometers. These methods lack the capacity to provide insights into blood glucose dynamics 24/7. Recognizing this gap, the current study aims to utilize continuous glucose monitoring to examine the impact of daily vinegar ingestion on glucose variability in adults identified as glucose intolerant.
Primary Outcome
The average blood glucose concentration for each 4-day period
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Liquid vinegar
- DIETARY_SUPPLEMENT vinegar pill
Study Locations (1)
Arizona
- 850 PBC - Phoenix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2024-03-26 |
| Est. Completion | 2025-07-15 |
| Phase | NA |
What the finished NCT06319443 record still lists
NCT06319443 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 3,858-participant average among 14 other Glucose Intolerance trials with a reported enrollment target (100% lower).
The record links to 1 condition, with Glucose Intolerance appearing as the primary indexed condition, and to 2 interventions - of which Liquid vinegar is the first listed.
NCT06319443 reports a single indexed study location in Arizona.
Frequently Asked Questions
What is clinical trial NCT06319443 about?
NCT06319443 is a clinical study titled "Daily Vinegar Ingestion and 24-Hour Blood Glucose Control". When linking dietary interventions and blood glucose management, much of the existing research - particularly studies exploring the effects of vinegar - has relied on discrete readings from the conventional testing methods: blood samples or glucometers. These methods lack the capacity to provide ins...
What is the current status of trial NCT06319443?
This trial is currently completed. It is a NA study. The enrollment target is 10 participants. The study started on 2024-03-26. Estimated completion is 2025-07-15.
What conditions does trial NCT06319443 study?
This clinical trial studies the following conditions: Glucose Intolerance.
What interventions are being tested in trial NCT06319443?
The interventions under investigation include: Liquid vinegar (DIETARY_SUPPLEMENT), vinegar pill (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT06319443?
This trial is sponsored by Arizona State University, which has 187 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06319443 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glucose Intolerance
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06319443's enrollment target sits among peer trials
10 14th of 14 higher than 1 of 14 other Glucose Intolerance trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Glucose Intolerance trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Impact of Overnight Nutrition Support on Sleep and Circadian Rhythm Disruption in the ICU
RECRUITING · NA
-
Time to Move in Pregnancy Hyperglycemia
RECRUITING · NA
-
The Impact of Removal of Exercise on Glycemic Control and Vascular Health in Older Active Adults
RECRUITING · NA
-
Sleep and Metabolism
RECRUITING · NA
-
The Acute T-Rex (Timing of Resistance Exercise) Study
RECRUITING · NA
-
Use of Continuous Glucose Monitoring in Non-Diabetic Population to Compliment Signos Mobile Health Platform
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI